This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Apple Tree Partners
Drug Names(s): Buprenorphine hydrochloride and ethylene vinyl acetate
Description: Probuphine utilizes Titan's ProNeura drug delivery system to deliver buprenorphine. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa opioid receptor. Titan's ProNeura drug delivery system consists of a small, solid rod made from a mixture of ethylene vinyl acetate (EVA) and drug substance, in this case, buprenorphine. The resulting product is a solid matrix that releases buprenorphine slowly, through the process of diffusion. The product is placed subcutaneously, normally in the upper arm in a simple 15-minute office procedure, and is removed in a similar manner at the end of the treatment period.
Titan and Braeburn
In December 2012, Titan Pharmaceuticals announced the signing of a license agreement with Braeburn Pharmaceuticals, wholly owned by Apple Tree Partners. The license grants Braeburn exclusive commercialization rights in the United States and Canada to the investigational product Probuphine. Under the terms of the agreement, Titan will remain responsible for any expenses associated with the support of the current NDA review process. Upon completion of the FDA review process, Braeburn Pharmaceuticals will assume all responsibility for commercialization and further clinical development of Probuphine in the U.S. and Canada.
In May 2013, Titan entered into an amendment to its license agreement with Braeburn for the exclusive commercialization rights in the U.S. and Canada to Probuphine. The amendment primarily modifies certain of the agreement's termination provisions by providing Braeburn the right to terminate the license in the event significant...See full deal structure in Biomedtracker
Partners: Titan Pharmaceuticals, Inc. Knight Therapeutics Inc.
Additional information available to subscribers only: